ESMO 2026: Qilu's QL1706 Posts 30.95-Month OS in Phase 3 First-Line Cervical Cancer
Start here
At ESMO 2026, Qilu Pharmaceutical reported phase 3 overall survival of 30.95 months for QL1706, a PD-1/CTLA-4 bispecific antibody, plus chemotherapy with or without bevacizumab as first-line treatment of persistent, recurrent or metastatic cervical cancer.
Excerpted from WeChat
Coverage timeline
Follow the coverage to see the different angles.
- WeChatPickESMO 2026: Qilu's QL1706 Posts 30.95-Month OS in Phase 3 First-Line Cervical Cancer
At ESMO 2026, Qilu Pharmaceutical reported phase 3 overall survival of 30.95 months for QL1706, a PD-1/CTLA-4 bispecific antibody, plus chemotherapy with or without bevacizumab as first-line treatment of persistent, recurrent or metastatic cervical cancer.
Coverage and heat for this story
Reports so far 1·Heat now 8·Peak heat 10 (Oct 19 10:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.